| Peter A Eriksson, MD | |
|
121 Central St W, Bagley, MN 56621-4393 | |
| (218) 694-6281 | |
| Not Available |
| Full Name | Peter A Eriksson |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 32 Years |
| Location | 121 Central St W, Bagley, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053338913 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 37732 (Minnesota) | Secondary |
| 207Q00000X | Family Medicine | 37732 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Essentia Health Fosston | Fosston, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Care Medical Services | 3678542842 | 18 |
News Archive
Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for nanodomains and transmitter release," in Nature Neuroscience on Oct. 17, 2010.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.
› Verified 7 days ago
| Entity Name | Department Of Health & Human Services Phs Ihs |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194754382 PECOS PAC ID: 7517879794 Enrollment ID: O20031105000353 |
News Archive
Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for nanodomains and transmitter release," in Nature Neuroscience on Oct. 17, 2010.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.
› Verified 7 days ago
| Entity Name | Phs Indian Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809765 PECOS PAC ID: 4789598731 Enrollment ID: O20031114000287 |
News Archive
Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for nanodomains and transmitter release," in Nature Neuroscience on Oct. 17, 2010.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter A Eriksson, MD 1702 University Dr S, Fargo, ND 58103-4940 Ph: () - | Peter A Eriksson, MD 121 Central St W, Bagley, MN 56621-4393 Ph: (218) 694-6281 |
News Archive
Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
NJIT Associate Professor Victor Matveev, PhD, in the department of mathematical sciences, was part of a research team that published "N-type Ca2+ channels carry the largest current: Implications for nanodomains and transmitter release," in Nature Neuroscience on Oct. 17, 2010.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.
› Verified 7 days ago
Esther Potti, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 4th St Nw, Bagley, MN 56621 Phone: 218-694-2384 Fax: 218-694-6687 | |
Ram Prasad Paneru, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 4th St Nw, Bagley, MN 56621 Phone: 218-694-2384 Fax: 218-694-6687 |